Scientific Programme
ISLB 2021 Annual Meeting
October 22nd 2021 - Virtual Congress
Who should attend?
-
Translational/clinical researchers
-
Physicians
-
Pathologists, Molecular Pathologists and Molecular Biologists
-
Oncologists
-
Clinical trainees, PhD and other students
-
Industry and Molecular diagnostics sector
-
Patients associations and advocacy
All lectures will be available to watch on demand from: October 22nd 2021, at 8:00 AM CET TIME
ISLB AWARDS LECTURES
.png)
Dr Charles Swanton 10:00 am CEST
.png)
The Francis Crick Institute - Cancer Research UK - University College London Cancer Institute, UK
Tumor evolution through Liquid Biopsy
%20(1).png)
Dr Catherine Alix-Panabieres 10:00 am CEST
.png)
The Laboratory 'Cellules Circulantes Rares Humaines ' (LCCRH) University Medical Center of Montpellier in France (University of Montpellier - UM), France
Role of Circulating Tumor Cells in Metastatic Cascade
.png)
TRACK 1 Basic and Discovery Research of Liquid Biopsy
.png)
Dr Juan Manuel Falcón
Ikerbasque Research Professor at CIC bioGUNE, Derio, Bizkaia, Spain
Use of metabolomics to understand treatment resistance
.png)
Dr Sabine Kasimir-Bauer
Associate Professor, University of Duisburg Essen, Germany
Phenotypic and functional analyses of CTC : Sab

Dr Nicola Aceto
Swiss Federal Institute of Technology (ETH) Zurich, Switzerland
Biology and vulnerabilities of CTC clusters

Dr Qiang Zang
Robert H Lurie Comprehensive Cancer Center, Northwestern University,
Chicago, Illinois, USA
Culture of Circulating Tumor Cells reality and xenograft
.png)
Dr Héctor Peinado
Spanish National Cancer Research Centre (CNIO), Madrid, Spain
Metastatic niche and Extracellular Vesicles
.png)
Dr Kenneth O'Byrne
Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, Australia
Novel diagnostic exosomal protein and genomic biomarkers in cancer
.png)
INDUSTRY SPONSORED LECTURES
_edited.png)
Stephanie Jordaens PhD
Biomedical Scientist, NOVOSANIS, Belgium
Urine as the golden sample for cancer biomarker detection
TRACK 2 Translational Research in Liquid Biopsy
Controversy session: Copy Number Variation evaluation in Liquid Biopsy
.png)
CONS ► Dr Lynette M. Sholl
Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
.png)
PROS ► Dr Philip Mack
University of California Davis Comprehensive Cancer Center, Sacramento, CA - Mount Sinai Tisch Cancer Institute, New York, NY, USA
.png)
Dr Miguel Angel Molina-Vila
Pangaea Oncology, Quirón Dexeus University Hospital, Barcelona, Spain
RNA analysis liquid biopsies of cancer patients: from fusion detection to gene signatures

Dr Christian Rolfo
Mount Sinai Medical System & Icahn School of Medicine, Mount Sinai, New York, NY, USA
ISLB President - Congress welcome and introduction
.png)
Dr Federica Di Nicolantonio
Laboratory Molecular Oncology at the Candiolo Cancer Institute IRCCS - Candiolo (Torino), Italy
Molecular mechanisms of cell free DNA release by colorectal cancer
.png)
Dr Umberto Malapelle
Department of Public Health, University of Naples Federico II, Naples, Italy
Molecular mechanisms of cell free DNA release in solid tumors
.png)
TRACK 3 Current clinical application of Liquid Biopsy
.png)
Dr Natasha Leighl
Medical Oncology, Princess Margaret, Toronto, ON, Canada
How to balance Next Generation Tumor Tissue testing versus Liquid Biopsy algorithms in the clinic
.png)
Dr Charu Aggarwal
Dept of Medicine, Division of Hem/Onc, University of Pennsylvania, PA, USA
Identifying mechanisms of Acquired Resistance in Oncogene-driven Cancers
.png)
Dr Maria E. Arcila
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Liquid Biopsy: Institutional testing platforms versus Central Laboratory
.png)
Dr Sarah-Jane Dawson
University of Melbourne, Australia
Liquid biopsy for targeting treatment resistance in Breast Cancer: A moving target
.png)
Dr Heinz Josef Lenz
University of South California USC, USA
Molecular Landscape in Colorectal Cancer: Opportunities for Liquid Biopsy
.png)
Dr Chiara Cremolini
University of Pisa, Azienda Ospedaliero-Universitaria Pisana, at the Tuscan Tumor Institute in Pisa, Toscana, Italy
ctDNA for treatment selection and treatment resistance in colon cancer
.png)
Dr Sergio Marchini
IRCCS, Humanitas Research Hospital, Milan, Italy
Clinical application of liquid biopsies to detect somatic BRCA1/2mutation in ovarian cancer

Dr Johann De Bono
The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK
Clinical Utility of Liquid Biopsy in Advanced Prostate Cancer
.png)
Dr David Gandara
Department of Internal Medicine, UC Davis Comprehensive Cancer Center, Sacramento, California, USA
Liquid Biopsy in the clinical management of NSCLC patients
TRACK 4 Expanding clinical application of Liquid Biopsy
.png)
Dr Lillian Siu
Princess Margaret, Ontario, Canada
Circulating Biomarkers for Immunotherapy: How to integrate in clinical trials
.png)
Dr Pier Vitale Nuzzo
Dana Farber Cancer Institute, Boston, MA, USA
Epigenetic and Liquid Biopsy
.png)
Dr Alberto Bardelli
Candiolo Cancer Institute IRCCS - Candiolo (Torino), Italy
Liquid biopsy driven, interventional clinical trials in CRC

Dr Toni Choueiri
Dana Farber Cancer Institute, Boston, MA, USA
Integrating ctDNA and tissue genomic profiling in renal cancer
.png)
Dr Eloísa Jantus Lewintre
Universitat Politècnica de València, Spain
Characterization of circulating TCR repertoire.
Role as biomarker for immunotherapy in NSCLC
.png)
Dr Luis Raez
Memorial Healthcare System, Pembroke Pines, USA
Monitoring Clinical Outcomes with Liquid biopsies (cfDNA and cfRNA)
.png)
Dr Nicole Kruderer
Advanced Cancer Research Group, Kirkland, Washington
Comparative effectiveness of ctDNA in Breast Cancer
.png)
INDUSTRY SPONSORED LECTURES

Dr Leomar Y Ballester
University of Texas Health Science at Houston, USA
Analyzing Circulating Tumor DNA in the Cerebrospinal Fluid of Cancer Patients
TRACK 5 Future of Liquid Biopsy
.png)
Dr Andrés Cardona
Research director en "Luis Carlos Sarmiento Angulo" Cancer Treatment and Research Center (CTIC), Colombia
Pan-methylation analysis in liquid biopsy: a novel perspective
.png)
Dr Max Diehn
Stanford University, Stanford, CA, USA
Lung Cancer Screening
.png)
Dr Wishart David
University of Alberta, Edmonton, Alberta, Canada
Liquid Biopsy in Cancer Screening: The Contribution of Metabolomics
.png)
Dr Aadel Chaudhuri
Washington University School of Medicine, St. Louis, USA
The evolving role of MRD in Solid Tumors
.png)
Dr Maria Jose Serrano
Centro Pfizer – Universidad de Granada – Junta de Andalucía de Genómica e Investigación Oncológica (GENYO), Granada, Spain
Cancer interception beyond ctDNA
.png)
Dr Chris Abbosh
The Francis Crick Institute - Cancer Research UK - University College London Cancer Institute, UK
ctDNA Biomarker of Relapse After Resection in Early NSCLC
.png)
INDUSTRY SPONSORED LECTURES

David Spetzler, MS, PhD, MBA
Caris Life Sciences - President and Chief Scientific Officer, AZ, USA
Transforming Liquid Biopsy: Advancing Clinical Utility for Physicians and Patients
TRACK 6 Liquid Biopsy Clinical Application Challenges and Opportunities Worldwide
.png)
Dr Amy Moore
VP, Global Engagement and Patients Partnership LUNGevity, USA
Role of the advocacy in Liquid Biopsy
.png)
RN, ONC, Allison Gittens
Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA
Molecular Nursing: a new approach for testing increasing and Liquid Biopsy awareness
.png)
Dr Valeria Denninghoff
University of Buenos Aires (UBA) - National Council for Scientific and Technical Research (CONICET), Argentina
Clinical Application in Latin America: Why so complicated?
.png)
Dr Ullas Batra
Rajiv Gandhi Cancer Institute, Delhi, India
Clinical Application in India: It’s Universal Use a reality or a mirage?
.png)
Dr Ola Khorshid
National Cancer Institute, Cairo, Egypt
Clinical Application in MENA (Middle East and North Africa) Region: Different realities
.png)
Dr Cardinale Smith
Center for Thoracic Oncology, Tisch Cancer Institute, Icahn school of Medicine at Mount Sinai, New York, NY, USA
Disparities in Molecular Testing
.png)
Dana Connors
ILSA, Foundation for the National Institutes of Health, USA
ILSA community: a partnership for standardization of Liquid Biopsy

TBD
TBD
FDA Initiatives for Liquid Biopsy application and standardization
.png)
INDUSTRY SPONSORED LECTURES
